What is pathophysiology of Prostate cancer?

['ⵙⵎⴷ ⵜⴰⴱⵔⴰⵜ ⴰⴷ']

ⵎⴰⵜⵜⴰ ⵜⴰⴷⵉⵎⴰⵡⴰⵏⵜ ⵏ ⵓⴱⴰⵜⵓ ⵏ ⵍⴽⴰⵔⵙⵜⴰⵜ ⵏ ⴱⵔⵓⵙⵜⴰⵜ?

ⴷⴰ ⵉⵜⵜⴰⵡⵢ ⵓⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉ ⵏ ⵓⴽⵕⵥⵎ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ ⵖⵔ ⵉⵎⵉⴽⴰⵏⵉⵣⵎⵏ ⴷ ⵜⵎⴳⴳⵉⵜⵉⵏ ⵜⵉⴷⵙⵍⴰⵏⵉⵏ ⵏⵏⴰ ⵉⵜⵜⴰⵡⵉⵏ ⵙ ⵓⵙⴱⵓⵖⵍⵓ ⴷ ⵓⴱⵓⵖⵍⵓ ⵏ ⵜⵎⴰⴹⵓⵏⵜ.

ⵉⴳⴰ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵜⴰⴱⵔⵓⵜⵙⵜⴰⵜ ⵢⴰⵏ ⵓⴱⵓⵖⵍⵓ ⵉⵛⵇⵇⴰⵏ ⵉⵜⵜⵓⵙⴱⵓⵖⵍⵓⵏ ⵙⴳ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵜⴰⴱⵔⵓⵜⵙⵜⴰⵜ, ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⴳⵎⴰⵎ ⵉⵎⵥⵥⵉⵏ, ⵉⵍⴰⵏ ⵜⴰⵍⵖⴰ ⵏ ⵓⴽⵏⴰⵔⵢⵓ ⵉⵍⵍⴰⵏ ⴷⴷⴰⵡ ⵏ ⵓⴱⵍⵊⵉⴽ ⴳ ⵉⵔⴳⴰⵣⵏ.

ⴷⴰ ⵜⵙⵙⵓⴼⵖ ⵜⴱⵔⵓⵙⵜⴰⵜ ⵙⵉⵎⴰⵎⵉⵏ ⴼⵍⵓⵢⵉⴷ, ⵏⵏⴰ ⵉⵙⵎⵓⵜⵜⴳⵏ ⴰⵔ ⵉⵜⵜⴰⵡⵉ ⵙⵉⵎⴰⵎ.

ⵓⵔ ⵉⵜⵜⵡⴰⵙⵙⵏ ⵓⴳⴳⴰⵔ ⵏ ⵓⴳⴳⴰⵔ ⵏ ⵓⵙⵙⵏⵜⵍ ⵏ ⵓⴽⵕⴰⵏ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ, ⵎⴰⵛⴰ ⵜⵜⵡⴰⵙⵙⴰⵏ ⴽⵉⴳⴰⵏ ⵏ ⵜⵎⵏⵜⵉⵍⵉⵏ ⵏⵏⴰ ⵉⵙⵙⴷⵓⵙⵏ ⵜⵉⵍⴽⴰⵎⵉⵏ ⵏ ⵓⴱⵓⵖⵍⵓ ⵏ ⵜⵎⴰⴹⵓⵏⵜ.

ⵉⵍⵍⴰ ⴳⵉⵙⵏ ⵓⵣⵎⵣ, ⴰⵎⵣⵔⵓⵢ ⵏ ⵜⵡⴰⵛⵓⵏⵜ, ⵜⴰⵡⵙⵉⵜ ⴷ ⴽⵔⴰ ⵏ ⵉⵎⵓⵜⵜⵉⵢⵏ ⵉⵊⵉⵏⵉⵜⵏ.

ⵆⵉⵔⵛⵓⴾ ⵏ ⴱⵔⵓⵙⵜⴰⵜⵢ ⵢⵈⵈⴰⵍ ⴰ ⵉⵋⵋⴰⵏ ⴷⴰⵗ ⵉⵔⴳⴰⵣⴰⵏ ⵓⵉⵏ ⴰⵣⵣⴰⵎⴰⵏ, ⴷⴰⵔⴰⵜ ⴰⵋⵋⵓⵜ ⵏ ⵉⵛⵂⵉⴾⵉⵍⴰⵏ ⵉⵋⵋⴰⵏ ⴷⴰⵗ ⵉⵔⴳⴰⵣⴰⵏ ⵓⵉⵏ ⴰⵣⵣⴰⵎⴰⵏ ⵓⵉⵏ 65 ⵏ ⴰⵓⴰⵜⴰⵉ

ⵙ ⵓⵙⵏⵓⵃⵢⵓ, ⵉⵔⴳⴰⵣⵏ ⵉⵍⴰⵏ ⵓⵎⵣⵔⵓⵢ ⵏ ⵜⴰⵡⵊⴰ ⵏ ⵍⴽⴰⵏⵚⵉⵕ ⵏ ⵓⴱⵔⵓⵜⴰⵙⵜⴰⵜ ⵍⵍⴰⵏ ⴳ ⵡⴰⴷⴷⴰⴷ ⵉⵔⵡⴰⵏ, ⵣⵓⵏⴷ ⵉⵔⴳⴰⵣⵏ ⵏ ⵉⴼⵔⵉⵇⵢⴰ ⴰⵎⵉⵔⵉⴽⴰⵏⵉⵢⵏ ⴷ ⵉⵔⴳⴰⵣⵏ ⵏ ⵓⵥⵓⵕ ⵏ ⴽⴰⵔⴰⵢⵉⴱⵉⵢⵏ.

ⴷⴰ ⵉⵜⵜⵓⵙⵎⵓⵏ ⵓⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉ ⵏ ⵓⴽⵕⵥⵎ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ ⴳ ⵜⴳⵎⵉ ⵓⵔ ⵉⵜⵜⵓⵃⴹⴰⵏ ⴷ ⵓⴱⵟⵟⵓ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⴳ ⵓⴳⵏⵙⵓ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ.

ⵥⴹⴰⵕ ⴰⴷ ⵢⵉⵍⵉ ⵓⵢⴰ ⵙ ⵜⵎⵏⵜⵉⵍⵜ ⵏ ⵉⵎⵓⵜⵜⵉⵢⵏ ⵉⵊⵉⵏⵉⵜⵏ ⵏⵏⴰ ⴷ ⵢⵓⵡⵉⵏ ⵙ ⵓⵙⵙⴼⵔⴽ ⵉⴳⴳⵓⵜⵏ ⵏ ⴽⵔⴰ ⵏ ⵉⵎⵙⴽⴰⵔⵏ ⵏ ⵜⴳⵎⵉ ⵏⵖⴷ ⴰⵙⴱⴷⴷⵉ ⵏ ⵉⵊⵉⵏⵏ ⵉⵎⵙⴱⴷⴷⴰⵏ ⵏ ⵓⴽⵕⵕⵓⵙ.

ⵉⵖⵢ ⴰⴷ ⵢⴰⵡⵉ ⵓⵙⵏⴼⵍ ⴰⴷ ⴳ ⵜⴳⵎⵉ ⵓⵔ ⵉⵜⵜⵓⵙⵏⵎⴰⵍⵏ ⵏ ⵜⵖⵔⴰⵙⵉⵏ, ⵏⵏⴰ ⵉⵜⵜⴰⵡⵉⵏ ⵙ ⵜⵓⵚⴽⴰ ⵏ ⵓⵖⵢⴰⵢ.

ⵎⴽ ⴷⴰ ⵉⵜⵜⴱⵓⵖⵍⵓ ⵓⵖⵢⴰⵢ, ⵉⵖⵢ ⴰⴷ ⵉⴽⵛⵎ ⵙ ⵉⴳⵎⴰⵎⵏ ⴷ ⵉⴳⵎⴰⵎⵏ ⵉⵍⵍⴰⵏ ⵜⴰⵎⴰ ⵏⵏⵙ, ⵣⵓⵏⴷ ⵜⴰⴱⵍⴰⵍⵉⵜ, ⴷ ⵓⵖⵢⴰⵢ, ⴷ ⵜⴱⵍⴰⵍⵉⵜⵉⵏ ⵏ ⵉⵃⴰⴳⵉⵎⵏ ⵉⵍⵍⴰⵏ ⵜⴰⵎⴰ ⵏⵏⵙ.

ⴳ ⴽⵔⴰ ⵏ ⵡⴰⴷⴷⴰⴷⵏ, ⵉⵖⵢ ⴰⴷ ⵉⴱⴹⵓ ⵉⴼⵔⴰⵢⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵙⴳ ⵓⴱⵓⵖⵍⵓ ⴰⵎⵣⵡⴰⵔⵓ ⴷ ⴰⴷ ⵙⵙⴱⵖⵔⵏ ⵙ ⵜⴼⵓⵍⵉⵏ ⵢⴰⴹⵏⵉⵏ ⵏ ⵜⴼⴳⴳⴰ ⵙ ⵓⴱⵔⵉⴷ ⵏ ⵉⴷⴰⵎⵎⵏ ⵏⵖⴷ ⴰⵏⴳⵔⴰⵡ ⵏ ⵉⴷⴰⵎⵎⵏ, ⵢⴰⵜ ⵜⵎⴳⴳⵉⵜ ⵉⵜⵜⵡⴰⵙⵙⵏ ⵙ ⵓⴱⵓⵖⵍⵓ.

ⵉⴳ ⵜⴱⵉⴷⴷ ⵜⵖⵎⵉ ⵏ ⵍⴽⵓⵏⵚⵉⵕ, ⵉⵛⵇⵇⴰ ⵓⵙⵎⴽⵍ ⵏⵏⵙ.

ⵉⵖⵢ ⴰⴷ ⵢⵉⵍⵉ ⵓⴹⴼⵓⵕ ⵏ ⵍⴽⴰⵔⵙⵜⴰⵜ ⵏ ⵜⴰⵖⵢⴰⵢⵜ ⵙⴳ ⵉⵎⵙⴽⴰⵔⵏ ⵏ ⵉⵀⵓⵔⵎⵓⵏⵏ, ⵙⵍⴰⵡⴰⵏ ⴰⴽⴽⵡ ⵉⵀⵓⵔⵎⵓⵏ ⵏ ⵓⴱⵔⵓⵜⵉⵙⵜⵓⵔⵓⵏ.

ⵉⵖⵢ ⴰⴷ ⵉⵙⵎⵓⵙⵙⵓ ⵓⵜⵉⵙⵜⵓⵙⵜⵓⵔⵓⵏ ⴰⵙⴱⵓⵖⵍⵓ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ, ⴷ ⴽⵉⴳⴰⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜⵉⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ ⴰⵔ ⵙⵙⵉⵜⵉⵎⵏⵜ ⴰⴷ ⵙⵙⴷⵔⵓⵙⵏⵜ ⵉⵙⵡⵉⵔⵏ ⵏ ⵓⵀⵓⵔⵎⵓⵏ ⴰⴷ ⵏⵖⴷ ⴰⴷ ⵙⴱⴷⴷⵏⵜ ⵜⵉⵍⴽⴰⵎⵉⵏ ⵏⵏⵙ.

ⴳ ⵓⵙⴳⵓⵎ, ⵜⴰⴱⴰⵜⵓⴼⵉⵣⵉⵓⵍⵓⵊⵉⵜ ⵏ ⵓⴽⵕⵥⵎ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ ⴷⴰ ⵜⵙⵙⴽⵛⵎ ⵜⵉⴳⵎⵉ ⵓⵔ ⵉⵜⵜⵓⵃⴹⴰⵏ ⴷ ⵓⴱⵟⵟⵓ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⴳ ⵓⴳⵏⵙⵓ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ, ⵏⵏⴰ ⵉⵖⵉⵏ ⴰⴷ ⵢⵉⵍⵉ ⴳ ⵓⵙⵏⴼⵍ ⵙ ⵉⵎⵙⴽⴰⵔⵏ ⵉⵊⵉⵏⵉⵜⵏ ⴷ ⵉⵀⵓⵔⵎⵓⵏⵏ ⴷ ⵉⵎⵙⴽⴰⵔⵏ ⵏ ⵜⵡⵏⵏⴰⴹⵜ.

ⵉⴳⴰ ⵓⵔⵎⴰⵙ ⵏ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⴱⵔⵙⵉⵡⴷ ⵏ ⵜⵎⴰⴹⵓⵏⵜ ⴰⴷ ⴰⵙⵉⵍⴰⵏ ⵉ ⵓⵙⴱⵓⵖⵍⵓ ⵏ ⵜⵊⵉⵊⵊⵉⵜⵉⵏ ⵉⵕⵡⴰⵏ ⴷ ⵓⵙⵖⵓⴷⵓ ⵏ ⵜⵢⴰⴼⵓⵜⵉⵏ ⵉ ⵢⵉⵎⵓⴹⵉⵏⵏ ⵉⵍⴰⵏ ⵍⴽⴰⵕⵙⵜⵕ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ.

['ⵉⵙⵓⵎⴰⵔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.

Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.

Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.

Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.

Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.

Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.

['ⴰⵙⴱⴷⵉⴷ: ⴰⵎⵙⵏⵉⵊⵊⵉ']

['ⴰⵙⵉⵜ ⴰⴷ ⵉⵜⵜⵓⴼⴽⴰ ⵖⴰⵙ ⵉ ⵓⵡⵜⵜⴰⵙ ⵏ ⵓⵙⵙⵍⵎⴷ ⴷ ⵓⵙⵏⵖⵎⵙ, ⵓⵔ ⵉⴳⵉ ⴰⵙⴼⴽ ⵏ ⵓⵎⵛⴰⵡⴰⵕ ⵏ ⵓⴷⵓⵙⵜⵓⵔ ⵏⵖⴷ ⵜⵡⵓⵔⵉⵡⵉⵏ ⵜⵉⵣⵣⵓⵍⴰⵏⵉⵏ.']

['ⵓⵔ ⵉⵇⵇⵉⵏ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵔⵙ ⵓⵎⵍⴰⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵎⵔⵙ ⵏ ⵓⵙⵎⵉⴳⵍ ⵏⵖⴷ ⵓⵙⵓⵊⵊⵉ ⵏ ⵜⵎⵓⴽⵔⵉⵙⵜ ⵏ ⵜⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵎⴰⴹⵓⵏⵜ, ⴷ ⵡⵉⵏⵏⴰ ⵉⵔⴰⵏ ⴰⵙⵇⵇⵙⵉ ⴰⵎⵙⵏⵉⵊⵊⵉ ⴰⵡⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⵉⵇⵇⴰⵏ ⴰⴷ ⵙⴰⵡⵍⵏ ⴷ ⵓⵎⵙⵏⵉⵊⵊⵉ ⵉⵜⵜⵓⵥⵍⴰⵢⵏ.']

['ⵙ ⵡⴰⵍⵍⵍⵉ ⵉⵜⵜⵓⵢⴰⵏⵏⴰ, ⵜⴰⵔⴰⵜⵙⴰ ⵏ ⵓⵏⵢⵓⵔⴰⵍ ⵏⵏⴰ ⵉⵜⵜⴰⴽⴽⴰⵏ ⵜⵉⵎⵔⴰⵔⵓⵜⵉⵏ ⵉ ⵉⵙⵇⵙⵉⵜⵏ, ⵓⵔ ⴷⴰ ⵜⵜⵉⵍⵉ ⴰⴽⴽⵡ ⵜⵓⵙⴷⵉⴷⵜ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵓⵡⵏⵖ ⵏ ⵓⵟⵟⵓⵏ. ⵙ ⵓⵎⴷⵢⴰ, ⵓⵟⵟⵓⵏ ⵏ ⵎⴷⴷⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ ⵖⴼ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵥⵍⵉⵏ.']

['ⵚⵓⴰⵍ ⵙⵓⵍ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⵏⵏⴽ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⵙⵙⵉⵡⵍ ⵏ ⵜⴷⵓⵙⵉ ⵢⴰⴹⵏ ⵉⵇⴱⵍⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ. ⵓⵔ ⴰⴽⴽⵡ ⴰⴷ ⵜⵙⵙⴼⵍⴷ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⴰⵣⵣⵓⵍⴰⵏ ⵏⵖⴷ ⴰⴷ ⵜⵣⴰⵢⴷ ⴳ ⵓⵙⵓⵜⴳ ⵏⵏⵙ ⴰⵛⴽⵓ ⵏⵜⵜⴰⵜ ⴰⵢⴷ ⵜⵙⵙⵖⵔⴷ ⴳ ⵓⵙⵉⵜ ⴰⴷ. ⵎⴽ ⵜⵓⵔⴷⴰ ⴰⴷ ⵖⵓⵔⴽ ⵉⵍⵍⴰ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵉⵣⵣⴳⵔⵏ, ⵙⵎⴷ 911 ⵏⵖⴷ ⴰⴷ ⴷⵉⴷⵜ ⵜⴰⵍⵙ ⴷⴰⵔ ⵜⴰⴷⴰⵍⴰ ⵏ ⵓⵣⵣⵔⴰⵢ ⵏ ⵣⵉⴽⴽ. ⵓⵔ ⵜⵍⵍⴰ ⵜⵓⵇⵇⵏⴰ ⵏ ⵓⵊⵉⵊⵊⵉ ⴷ ⵓⵎⵏⵉⴳ ⵙ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ. ⵓⵔ ⴷⴰ ⵜⵙⴽⴰⵔ ⴱⵢⵓⵎⵉⴷⵍⵉⴱ ⵏⵖⴷ ⵉⵎⵙⵡⵓⵔⵉⵏ ⵏⵏⵙ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⴷⵔⴰⵡ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⴽⵔⴰ ⵏ ⵓⵙⵎⴷⵢⴰ, ⵙ ⵡⴰⵡⴰⵍ ⵏⵖⴷ ⵙ ⵓⵙⵏⵓⵎⵍ, ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵍⵍⴰⵏ ⴳ ⵓⴷⵖⴰⵔ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ.']

['ⴰⵙⴱⴰⴷⵓ: ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⴼⵓⵙ']

['ⴰⵛⵔⵓⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ']

['ⵎⴽ ⵜⵛⵛⵉⵖⴰⵍⴷ ⵙ ⵜⵛⵛⵉⵢⵜ ⵎⴰⵙⴷ ⴽⵔⴰ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ ⵏⵏⴰ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵏⵖⴷ ⵜⵉⵙⵏⵙⵉ ⵏⵏⵓⵏ ⴷⴰ ⵉⴽⵛⵎⵏ ⴳ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵣⵔⴼ ⵏⵏⵓⵏ, ⵜⵣⵎⵔⴷ ⴰⴷ ⵜⴰⵍⵙⴷ (ⵏⵖ ⴰⵎⴷⵢⴰⵣ ⵏⵏⴽ) ⴰⴷ ⵜⵙⵏⵎⵍⴷ ⵉ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵙ ⵓⵙⵓⵜⵔ ⵏ ⵓⵙⵙⵉⴷⴼ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ, ⵏⵖⴷ ⴰⴷ ⵜⴱⴷⴷⴷ ⵜⵉⵍⵉⵜ ⵏⵏⵙⵏ.']

['ⵉⵏⴰⵓⴰⵏ ⴰⵂⴰⵏ ⴰⴾⵜⴰⴱ ⵙ ⴰⵍⴾⵉⵜⵜⴰⴱ ⵙ ⵎⵢⵍ (ⵉⴾⵉⴰⴷ ⵙ ⴰⴾⵜⴰⴱ "ⵎⵢⵍ" ⵉ ⵎⵢⵍ)']

['DMCA ⵜⵙⵙⵓⵜⵔ ⴰⵙⵎⵉⵙⵉ ⵏⵏⴽ ⵏ ⵓⵎⴳⴰⵍ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵉⴽⵛⵎ ⴳ ⵓⵙⵎⵎⴰⵍ ⴰⴷ: (1) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵡⵓⵔⵉ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵜⵍ ⵏ ⵓⵎⴳⴰⵍ; (2) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵓⵎⴰⵢⵜ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⴷ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵅⵚⵚⴰⵏ ⴰⴼⴰⴷ ⴰⴷ ⵏⴰⴼ ⵜⵓⵎⴰⵢⵜ; (3) ⵉⵏⵖⵎⵉⵙⵏ ⵏ ⵓⵎⵢⴰⵡⴰⴹ ⴰⴽⴷⴽ, ⴳ ⵉⵍⵍⴰ ⵡⴰⵏⵙⴰ ⵏⵏⴽ, ⵓⵟⵟⵓⵏ ⵏ ⵜⵉⵍⵉⴼⵓⵏ ⴷ ⵡⴰⵏⵙⴰ ⵏ ⵓⵍⵉⴽⵜⵕⵓⵏ; (4) ⴰⵙⵉⵡⴹ ⵏⵏⴽ ⵎⴰⵙ ⴷⴰⵔⴽ ⵜⴰⵍⵍⵉⵍⵜ ⵉⵖⵓⴷⴰⵏ ⵏ ⵓⵙⵏⴽⴷ ⵎⴰⵙ ⵜⵓⵎⴰⵢⵜ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵏⵏⴰ ⵜⵙⵙⵔⴳⴰⵍ ⵓⵔ ⵜⴽⴽⵉ ⵜⵓⵔⴰⴳⵜ ⵙⴳ ⵖⵓⵔ ⵡⴰⵏⵏⴰ ⵉⵟⵟⴰⴼⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ, ⵏⵖⴷ ⴰⵎⴷⵢⴰⵣ ⵏⵏⵙ, ⵏⵖⴷ ⵙ ⵓⵙⵡⵓⵔⵉ ⵏ ⴽⵔⴰ ⵏ ⵓⵙⵍⴳⵏ; ']

['(5) ⴰⵙⵉⵙⵙⵉⴾⵉ ⵏⵢⵜ, ⵉⴾⴼⴰⵏ ⵙ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⵜⵉⴷⵉⵜ, ⴰⵙ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵏⴰⵙⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⴷ ⴰⵙ ⵉⵍⴰ ⴰⴾⴰⵉⴰⴷ ⵉ ⴰⵙⵓⵋ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵜⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉ ⴰⵋⵋⴰⵏⵢⵏ']

['ⴷ (6) ⴰⴾⴰⵔⵓⵙ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵎⵢⵗ ⵓⴰ ⵉⵋⵋⴰⵏ ⵙ ⵢⵎⵢⵍ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ']

['ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵙⴰⴾⵏⵢ ⵏ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⴰⵋⵋⵓⵜⵏⵢⵏ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵢⵈⵈⵉⵍ ⴰⵙⵉⵓⴰⴷ ⵏ ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏⵢⵜ']

['ⴰⵎⵢⴰⵡⴰⴹ']

['ⵙⵓⴾⵢⵍ ⵉⵢⵎⴰⵍ ⵉⵢⵎⴰ ⵙ ⴽⴰⴾⴰⵎⴰⵍ ⴰⵙⵉⵙⵜⴰⵏ/ⴰⵙⵓⵋ']

What is pathophysiology of prostate cancer?

The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.

Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.

The prostate gland produces seminal fluid, which nourishes and transports sperm.

The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.

These include age, family history, race, and certain genetic mutations.

Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.

Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.

The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.

This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.

These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.

As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.

In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.

Once the cancer has spread, it can be more difficult to treat.

Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.

Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.

In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.

Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ⴰⵜⵜⴰⵢⵏ']

['ⴷⴰ ⵉⵙⵙⵎⵔⴰⵙ ⴱⵢⵓ ⵎⵉⴷⵍⵍⵉⴱ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⵙⵉⴳⴳⵍ ⵉⵎⵉⴽⵙⵉⵍⵏ (ⴰⵍⴳⵓⵔⵉⵜⵎ ⵏ ⵓⵍⵎⵎⵓⴷ ⵏ ⵉⵎⵉⵙ) ⵉ ⵓⵙⵓⴼⵖ ⵏ ⵉⵎⵣⵉⵏⵏ ⵏ ⵉⵙⵇⵙⵉⵜⵏ ⴷ ⵜⵎⵔⴰⵔⵓⵜⵉⵏ.']

['ⴷⴰ ⵏⵙⵙⵏⵜⵉ ⵙ 35 ⵎⵍⵢⵓⵏ ⵏ ⵜⵥⵕⵉⴳⵉⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜ ⵜⴰⴱⵢⵓⵎⵉⴷⵉⴽⵜ ⵏ ⴱⴰⴱⵎⵉⴷ/ⵎⵉⴷⵍⵉⵏ. ⵓⵍⴰ ⴰⵡⴷ ⵜⵉⴼⵔⴽⵉⵏ ⵏ ⵡⵉⴱ ⵏ ⵔⴰⴼⵉⵏⴷⵡⵉⴱ.']

['ⴰⵜ-ⵓ-ⴰⵗ "ⴰⵍⵓⴰⵈⴰⵏ" ⴰⴷ "ⴰⴾⴼⴰⵣ"']